In recent years Lilly has implemented a Next Generation Research (NGR) initiative to improve the value output of the R&D portfolio. One of the NGR pillars focuses on decreasing the timeline to bring medicines to patients. As part of this initiative Lilly has invested in an ‘Islands of Automation’ approach to advance the B cell antibody discovery platform at the Lilly Biotechnology Center in San Diego with the goal of significantly increasing throughput and reducing project timelines. This talk will focus on the automated systems that have been developed as part of this platform beginning with B cells sorted into microtiter plates through binding and functional assays run in dose response plates from recombinantly expressed material. Examples of alternative instruments to traditional methods and software solutions to eliminate inefficiencies will be shared. This highly automated approach to antibody discovery has allowed us to meet aggressive timelines and dramatically increase throughput while allowing flexibility for future changes to our process.